Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Asenapine Clear all
Completed Phase 4 Interventional Results available

Asenapine in the Treatment of Older Adults With Bipolar Disorder

NCT01460290
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Asenapine
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 1, 2026, 1:44 PM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 1, 2026, 1:44 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Treating Acutely Agitated Patients With Asenapine Sublingual Tablets

NCT01400113
View directory record Official record
Conditions
Agitation
Interventions
Asenapine, Placebo
Drug
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

NCT01395992
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
asenapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 1, 2026, 1:44 PM EDT
Completed No phase listed Observational

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

NCT04002700
View directory record Official record
Conditions
Stroke
Interventions
Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,234,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 1, 2026, 1:44 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

NCT01684657
View directory record Official record
Conditions
Stuttering
Interventions
Asenapine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 1, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional

Asenapine for Bipolar Depression

NCT01807741
View directory record Official record
Conditions
Bipolar Depression
Interventions
Asenapine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

NCT01396291
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
asenapine, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
Anaheim, California • Chino, California • Escondido, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

NCT01670019
View directory record Official record
Conditions
Major Depressive Disorder Without Psychotic Features
Interventions
Asenapine 5-20 mg daily, Placebo 1-4 tablets daily
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

NCT00806234
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 19 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

NCT02876900
View directory record Official record
Conditions
Schizophrenia
Interventions
Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, Placebo
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Once-Daily Asenapine for Schizophrenia

NCT01549041
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine 10 mg daily in the evening, Asenapine 5 mg twice daily
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Butner, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

NCT01587118
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Adjunctive asenapine
Drug
Lead sponsor
Lori Davis, MD
Other
Eligibility
19 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 1, 2026, 1:44 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study Between SAPHRIS and Asenapine

NCT01948024
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SAPHRIS, Asenapine
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Costa Mesa, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 1, 2026, 1:44 PM EDT